Synergy CHC (SNYR) Competitors $3.33 -0.07 (-2.06%) As of 12:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. MIST, GNLX, PLX, BHST, CRDL, ACTU, ONCY, KYTX, TARA, and ATOSShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include Milestone Pharmaceuticals (MIST), Genelux (GNLX), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), Cardiol Therapeutics (CRDL), Actuate Therapeutics (ACTU), Oncolytics Biotech (ONCY), Kyverna Therapeutics (KYTX), Protara Therapeutics (TARA), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors Milestone Pharmaceuticals Genelux Protalix BioTherapeutics BioHarvest Sciences Cardiol Therapeutics Actuate Therapeutics Oncolytics Biotech Kyverna Therapeutics Protara Therapeutics Atossa Genetics Synergy CHC (NASDAQ:SNYR) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Is SNYR or MIST more profitable? Synergy CHC's return on equity of -8.48% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHCN/A -8.48% 12.75% Milestone Pharmaceuticals N/A -329.85%-67.20% Do analysts rate SNYR or MIST? Synergy CHC currently has a consensus price target of $10.00, indicating a potential upside of 200.30%. Milestone Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 325.53%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Synergy CHC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has preferable earnings and valuation, SNYR or MIST? Synergy CHC has higher revenue and earnings than Milestone Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$33.59M0.91$2.12MN/AN/AMilestone Pharmaceuticals$1M87.94-$41.52M-$0.78-2.11 Do institutionals & insiders believe in SNYR or MIST? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 56.6% of Synergy CHC shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor SNYR or MIST? In the previous week, Milestone Pharmaceuticals had 16 more articles in the media than Synergy CHC. MarketBeat recorded 17 mentions for Milestone Pharmaceuticals and 1 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 1.87 beat Milestone Pharmaceuticals' score of 0.28 indicating that Synergy CHC is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Very Positive Milestone Pharmaceuticals Neutral SummarySynergy CHC beats Milestone Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$30.62M$33.03B$16.07B$9.30BDividend YieldN/A2.63%3.13%4.03%P/E RatioN/A32.0419.6719.64Price / Sales0.911.8145.86188.30Price / Cash12.7416.3514.7257.93Price / Book-1.748.376.035.63Net Income$2.12M$1.19B$691.68M$257.73M7 Day Performance7.42%-1.77%1.45%0.07%1 Month Performance45.41%1.03%0.91%8.32%1 Year PerformanceN/A30.61%3.64%13.78% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC3.9033 of 5 stars$3.33-2.1%$10.00+200.3%N/A$30.62M$33.59M0.0040Positive NewsMISTMilestone Pharmaceuticals2.7335 of 5 stars$2.26+4.1%$7.00+209.7%-6.6%$120.82M$1M-2.9030Analyst RevisionGNLXGenelux1.1999 of 5 stars$3.20+10.3%$17.75+454.7%+17.6%$120.75MN/A-3.6410Gap DownPLXProtalix BioTherapeutics2.8014 of 5 stars$1.50+2.1%$15.00+899.1%+19.0%$119.51M$59.76M-11.55200Gap UpBHSTBioHarvest SciencesN/A$7.19+1.8%$13.67+90.1%N/A$118.10M$27.70M-14.38N/ACRDLCardiol Therapeutics2.4309 of 5 stars$1.43-1.7%$8.00+461.4%-39.4%$117.78MN/A-4.1920Positive NewsACTUActuate Therapeutics2.7248 of 5 stars$5.94-1.2%$20.50+245.1%N/A$116.54MN/A0.0010Positive NewsONCYOncolytics Biotech1.4803 of 5 stars$1.23+21.8%$4.33+252.3%+4.6%$115.96MN/A-4.2430High Trading VolumeKYTXKyverna Therapeutics1.9932 of 5 stars$2.64+3.5%$18.50+600.8%-61.5%$114.10M$7.03M-0.7896TARAProtara Therapeutics2.3128 of 5 stars$2.88+2.9%$20.50+611.8%+28.2%$111.11MN/A-1.6730ATOSAtossa Genetics3.1476 of 5 stars$0.85-0.1%$6.17+629.8%-34.7%$109.15MN/A-4.028Positive News Related Companies and Tools Related Companies Milestone Pharmaceuticals Competitors Genelux Competitors Protalix BioTherapeutics Competitors BioHarvest Sciences Competitors Cardiol Therapeutics Competitors Actuate Therapeutics Competitors Oncolytics Biotech Competitors Kyverna Therapeutics Competitors Protara Therapeutics Competitors Atossa Genetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
